257 related articles for article (PubMed ID: 26359571)
1. FDG uptake in non-small cell lung cancer is not an independent predictor of EGFR or KRAS mutation status: a retrospective analysis of 206 patients.
Lee SM; Bae SK; Jung SJ; Kim CK
Clin Nucl Med; 2015 Dec; 40(12):950-8. PubMed ID: 26359571
[TBL] [Abstract][Full Text] [Related]
2. Role of [¹⁸F]FDG PET in prediction of KRAS and EGFR mutation status in patients with advanced non-small-cell lung cancer.
Caicedo C; Garcia-Velloso MJ; Lozano MD; Labiano T; Vigil Diaz C; Lopez-Picazo JM; Gurpide A; Zulueta JJ; Richter Echevarria JA; Perez Gracia JL
Eur J Nucl Med Mol Imaging; 2014 Nov; 41(11):2058-65. PubMed ID: 24990403
[TBL] [Abstract][Full Text] [Related]
3. Correlation of EGFR or KRAS mutation status with 18F-FDG uptake on PET-CT scan in lung adenocarcinoma.
Takamochi K; Mogushi K; Kawaji H; Imashimizu K; Fukui M; Oh S; Itoh M; Hayashizaki Y; Ko W; Akeboshi M; Suzuki K
PLoS One; 2017; 12(4):e0175622. PubMed ID: 28422979
[TBL] [Abstract][Full Text] [Related]
4. 18F-FDG uptake and EGFR mutations in patients with non-small cell lung cancer: a single-institution retrospective analysis.
Na II; Byun BH; Kim KM; Cheon GJ; Choe du H; Koh JS; Lee DY; Ryoo BY; Baek H; Lim SM; Yang SH; Kim CH; Lee JC
Lung Cancer; 2010 Jan; 67(1):76-80. PubMed ID: 19371962
[TBL] [Abstract][Full Text] [Related]
5. Standardized uptake value on (18)F-FDG-PET/CT is a predictor of EGFR T790M mutation status in patients with acquired resistance to EGFR-TKIs.
Yoshida T; Tanaka H; Kuroda H; Shimizu J; Horio Y; Sakao Y; Inaba Y; Iwata H; Hida T; Yatabe Y
Lung Cancer; 2016 Oct; 100():14-19. PubMed ID: 27597275
[TBL] [Abstract][Full Text] [Related]
6. The role of metabolic tumor volume (MTV) measured by [18F] FDG PET/CT in predicting EGFR gene mutation status in non-small cell lung cancer.
Liu A; Han A; Zhu H; Ma L; Huang Y; Li M; Jin F; Yang Q; Yu J
Oncotarget; 2017 May; 8(20):33736-33744. PubMed ID: 28422710
[TBL] [Abstract][Full Text] [Related]
7. Next-Generation Radiogenomics Sequencing for Prediction of EGFR and KRAS Mutation Status in NSCLC Patients Using Multimodal Imaging and Machine Learning Algorithms.
Shiri I; Maleki H; Hajianfar G; Abdollahi H; Ashrafinia S; Hatt M; Zaidi H; Oveisi M; Rahmim A
Mol Imaging Biol; 2020 Aug; 22(4):1132-1148. PubMed ID: 32185618
[TBL] [Abstract][Full Text] [Related]
8. Role of 18F-fluorodeoxyglucose positron emission tomography in predicting epidermal growth factor receptor mutations in non-small cell lung cancer.
Mak RH; Digumarthy SR; Muzikansky A; Engelman JA; Shepard JA; Choi NC; Sequist LV
Oncologist; 2011; 16(3):319-26. PubMed ID: 21339258
[TBL] [Abstract][Full Text] [Related]
9. Value of
Lv Z; Fan J; Xu J; Wu F; Huang Q; Guo M; Liao T; Liu S; Lan X; Liao S; Geng W; Jin Y
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):735-750. PubMed ID: 29164298
[TBL] [Abstract][Full Text] [Related]
10. Associations Between Somatic Mutations and Metabolic Imaging Phenotypes in Non-Small Cell Lung Cancer.
Yip SS; Kim J; Coroller TP; Parmar C; Velazquez ER; Huynh E; Mak RH; Aerts HJ
J Nucl Med; 2017 Apr; 58(4):569-576. PubMed ID: 27688480
[TBL] [Abstract][Full Text] [Related]
11. EGFR and KRAS mutation status in non-small-cell lung cancer occurring in HIV-infected patients.
Créquit P; Ruppert AM; Rozensztajn N; Gounant V; Vieira T; Poulot V; Antoine M; Chouaid C; Wislez M; Cadranel J; Lavole A
Lung Cancer; 2016 Jun; 96():74-7. PubMed ID: 27133754
[TBL] [Abstract][Full Text] [Related]
12. Using whole genome amplification (WGA) of low-volume biopsies to assess the prognostic role of EGFR, KRAS, p53, and CMET mutations in advanced-stage non-small cell lung cancer (NSCLC).
Lim EH; Zhang SL; Li JL; Yap WS; Howe TC; Tan BP; Lee YS; Wong D; Khoo KL; Seto KY; Tan L; Agasthian T; Koong HN; Tam J; Tan C; Caleb M; Chang A; Ng A; Tan P
J Thorac Oncol; 2009 Jan; 4(1):12-21. PubMed ID: 19096301
[TBL] [Abstract][Full Text] [Related]
13. [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].
Zhao J; Gao J; Guo L; Hu X; Liu Q; Zhao J; Liu L; Jiang J; Wang M; Liang Z; Xu Y; Chen M; Zhang L; Li L; Zhong W
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):617-622. PubMed ID: 28935015
[TBL] [Abstract][Full Text] [Related]
14. Imaging Characteristics of Driver Mutations in EGFR, KRAS, and ALK among Treatment-Naïve Patients with Advanced Lung Adenocarcinoma.
Park J; Kobayashi Y; Urayama KY; Yamaura H; Yatabe Y; Hida T
PLoS One; 2016; 11(8):e0161081. PubMed ID: 27518729
[TBL] [Abstract][Full Text] [Related]
15. PNA clamping-assisted fluorescence melting curve analysis for detecting EGFR and KRAS mutations in the circulating tumor DNA of patients with advanced non-small cell lung cancer.
Han JY; Choi JJ; Kim JY; Han YL; Lee GK
BMC Cancer; 2016 Aug; 16():627. PubMed ID: 27519791
[TBL] [Abstract][Full Text] [Related]
16. Phosphoinositide-3-kinase catalytic alpha and KRAS mutations are important predictors of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in patients with advanced non-small cell lung cancer.
Ludovini V; Bianconi F; Pistola L; Chiari R; Minotti V; Colella R; Giuffrida D; Tofanetti FR; Siggillino A; Flacco A; Baldelli E; Iacono D; Mameli MG; Cavaliere A; Crinò L
J Thorac Oncol; 2011 Apr; 6(4):707-15. PubMed ID: 21258250
[TBL] [Abstract][Full Text] [Related]
17. Correlation between EGFR gene mutation, cytologic tumor markers, 18F-FDG uptake in non-small cell lung cancer.
Cho A; Hur J; Moon YW; Hong SR; Suh YJ; Kim YJ; Im DJ; Hong YJ; Lee HJ; Kim YJ; Shim HS; Lee JS; Kim JH; Choi BW
BMC Cancer; 2016 Mar; 16():224. PubMed ID: 26979333
[TBL] [Abstract][Full Text] [Related]
18. EGFR mutation decreases FDG uptake in non‑small cell lung cancer via the NOX4/ROS/GLUT1 axis.
Chen L; Zhou Y; Tang X; Yang C; Tian Y; Xie R; Chen T; Yang J; Jing M; Chen F; Wang C; Sun H; Huang Y
Int J Oncol; 2019 Jan; 54(1):370-380. PubMed ID: 30431083
[TBL] [Abstract][Full Text] [Related]
19. Volume-based parameters measured by using FDG PET/CT in patients with stage I NSCLC treated with stereotactic body radiation therapy: prognostic value.
Satoh Y; Onishi H; Nambu A; Araki T
Radiology; 2014 Jan; 270(1):275-81. PubMed ID: 24029640
[TBL] [Abstract][Full Text] [Related]
20. Correlation between EGFR mutation status and F
Zhu L; Yin G; Chen W; Li X; Yu X; Zhu X; Jiang W; Jia C; Chen P; Zhang Y; Lu D; Yu L; Li X; Xu W
Thorac Cancer; 2019 Apr; 10(4):659-664. PubMed ID: 30776196
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]